GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Staar Surgical Co (NAS:STAA) » Definitions » Sloan Ratio %

Staar Surgical Co (Staar Surgical Co) Sloan Ratio % : -21.66% (As of Mar. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Staar Surgical Co Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Staar Surgical Co's Sloan Ratio for the quarter that ended in Mar. 2024 was -21.66%.

As of Mar. 2024, Staar Surgical Co has a Sloan Ratio of -21.66%, indicating there is a warning stage of accrual build up.


Staar Surgical Co Sloan Ratio % Historical Data

The historical data trend for Staar Surgical Co's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staar Surgical Co Sloan Ratio % Chart

Staar Surgical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.76 -2.58 -0.81 38.28 -13.83

Staar Surgical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.77 31.45 6.26 -13.83 -21.66

Competitive Comparison of Staar Surgical Co's Sloan Ratio %

For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staar Surgical Co's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Staar Surgical Co's Sloan Ratio % falls into.



Staar Surgical Co Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Staar Surgical Co's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(21.347-14.594
-74.347)/488.692
=-13.83%

Staar Surgical Co's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(15.298-41.368
-80.601)/492.535
=-21.66%

Staar Surgical Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 6.064 (Jun. 2023 ) + 4.817 (Sep. 2023 ) + 7.756 (Dec. 2023 ) + -3.339 (Mar. 2024 ) = $15.3 Mil.
Staar Surgical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -6.306 (Jun. 2023 ) + -5.975 (Sep. 2023 ) + 31.969 (Dec. 2023 ) + 21.68 (Mar. 2024 ) = $41.4 Mil.
Staar Surgical Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 10.172 (Jun. 2023 ) + 31.84 (Sep. 2023 ) + 22.402 (Dec. 2023 ) + 16.187 (Mar. 2024 ) = $80.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Staar Surgical Co  (NAS:STAA) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Staar Surgical Co has a Sloan Ratio of -21.66%, indicating there is a warning stage of accrual build up.


Staar Surgical Co Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Staar Surgical Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Staar Surgical Co (Staar Surgical Co) Business Description

Traded in Other Exchanges
Address
25651 Atlantic Ocean Drive, Lake Forest, CA, USA, 92630
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also make lenses which are used in surgery that treats cataracts. The company offers products are ICLs used in refractive surgery and IOLs used in cataract surgery. The company generated sales are from the ophthalmic surgical product segment.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Warren Foust officer: Chief Operating Officer 17 MAGNOLIA DRIVE, LADERA RANCH CA 92694
Magda Michna officer: Chief Clinical, Regulatory, C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618
Keith Holliday officer: V.P., Research & Development 1911 WALKER AVENUE, MONROVIA CA 91016
Robert Studholme officer: Senior VP, Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
James E Francese officer: VP, Global Marketing 1911 WALKER AVE, MONROVIA CA 91016
Caren L Mason director 2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025
Samuel J Gesten officer: VP, General Counsel 1911 WALKER AVENUE, MONROVIA CA 91016
Patrick F. Williams officer: Chief Financial Officer C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Hans-martin Blickensdoerfer officer: VP, International Marketing 1911 WALKER AVENUE, MONROVIA CA 91016
Lou Silverman director
Graydon C. Hansen officer: Sr. VP, Global Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630
Jon K. Hayashida officer: VP, Global Clinical, Medical 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630